Nonalcoholic fatty liver disease in normal weight subjects: current concepts and approaches (literature review)

Authors

  • Yu.M. Stepanov State Institution “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine
  • O.Yu. Zavhorodnia State Institution “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2308-2097.54.3.2020.211738

Keywords:

liver steatosis, steatohepatitis, nonalcoholic fatty liver disease in persons with normal weight, review

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD in normal-weight individuals represents a disease whose morphological substrate is liver steatosis, induced by a heterogeneous spectrum of etiological factors, ranging from eating habits (such as high fructose and dietary fats content), body composition (acquired or congenital lipodystrophy, sarcopenia), and genetic risk factors. About 20 % of these patients are diagnosed with steatohepatitis, demonstrating a histopathologic severity similar to patients with classic NAFLD. There are large gaps in our understanding of NAFLD among persons of normal weight, this literature review covers the main aspects of the etiology, pathogenesis, diagnosis, and therapeutic tactics of this condition.

Downloads

Download data is not yet available.

References

Shi Y, Wang Q, Sun Y, et al. The Prevalence of Lean/Nonobese Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2020;54(4):378-387. doi:10.1097/MCG.0000000000001270.

Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-97.e10. doi:10.1053/j.gastro.2015.04.043.

Bueverov AO, Bogomolov PO. Non-alcoholic fatty liver disease without obesity: the problem to be solved. Terapevticheskii arkhiv. 2017;89(12-2):226-232. doi:10.17116/terarkh20178912226-232.

Yoo JJ, Kim W, Kim MY, et al. Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol. 2019;25(1):1-11. doi:10.3350/cmh.2018.0037.

Kumar R, Mohan S. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. J Clin Transl Hepatol. 2017; 5(3):216-223. doi: 10.14218/JCTH.2016.00068.

Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1(4):329-341. doi:10.1016/j.jhepr.2019.08.002.

Feng RN, Du SS, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20(47):17932-17940. doi:10.3748/wjg.v20.i47.17932.

NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377-1396. doi:10.1016/S0140-6736(16)30054-X.

Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol. 2013;108(8):1299-1304. doi:10.1038/ajg.2013.104.

Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112-117. doi:10.7326/0003-4819-132-2-200001180-00004.

Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91(6):319-327. doi:10.1097/MD.0b013e3182779d49.

Kim D, Kim WR. Nonobese Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017;15(4):474-485. doi:10.1016/j.cgh.2016.08.028.

Younes R, Bugianesi E. NASH in Lean Individuals. Semin Liver Dis. 2019;39(1):86-95. doi:10.1055/s-0038-1677517.

Browning JD, Cohen JC, Hobbs HH. Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52(4):1189-1192. doi:10.1002/hep.23946.

Xu R., Tao A., Zhang S., Deng Y., Chen, G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Scientific reports, 2015; 5: 9284

Sliz E, Sebert S, Würtz P, et al. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Hum Mol Genet. 2018;27(12):2214-2223. doi:10.1093/hmg/ddy124.

Petta S, Valenti L, Tuttolomondo A, et al. Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology. 2017;66(6):1885-1893. doi:10.1002/hep.29395.

Nakatsuka A, Matsuyama M, Yamaguchi S, et al. Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis. Sci Rep. 2016;6:21721. Published 2016 Feb 17. doi:10.1038/srep21721.

Yousef MH, Al Juboori A, Albarrak AA, Ibdah JA, Tahan V. Fatty liver without a large "belly": Magnified review of non-alcoholic fatty liver disease in non-obese patients. World J Gastrointest Pathophysiol. 2017;8(3):100-107. doi:10.4291/wjgp.v8.i3.100.

Stefan N, Schick F, Häring HU. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 2017;26(2):292-300. doi:10.1016/j.cmet.2017.07.008.

Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology. 2017;66(6):2055-2065. doi:10.1002/hep.29420.

Nobili V, Marcellini M, Marchesini G, et al. Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care. 2007;30(10):2638-2640. doi:10.2337/dc07-0281.

Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601-609. doi:10.1002/hep.26093.

Fracanzani AL, Petta S, Lombardi R, et al. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clin Gastroenterol Hepatol. 2017;15(10):1604-1611.e1. doi:10.1016/j.cgh.2017.04.045.

Duarte SMB, Stefano JT, Miele L, et al. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. Nutr Metab Cardiovasc Dis. 2018;28(4):369-384. doi:10.1016/j.numecd.2017.10.014.

Heimerl S, Fischer M, Baessler A, et al. Alterations of plasma lysophosphatidylcholine species in obesity and weight loss. PLoS One. 2014;9(10):e111348. Published 2014 Oct 23. doi:10.1371/journal.pone.0111348.

Feldman A, Eder SK, Felder TK, et al. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol. 2017;112(1):102-110. doi:10.1038/ajg.2016.318.

Akyuz U, Yesil A, Yilmaz Y. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scand J Gastroenterol. 2015;50(3):341-346. doi:10.3109/00365521.2014.983160.

Kumar R, Rastogi A, Sharma MK, et al. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?. Indian J Endocrinol Metab. 2013;17(4):665-671. doi:10.4103/2230-8210.113758.

Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2009;203(2):581-586. doi:10.1016/j.atherosclerosis.2008.07.024.

Dela Cruz AC, Bugianesi E, George J, Day CP, Liaquat H, Charatcharoenwitthaya P. Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(5):S-909. doi:10.1016/S0016-5085(14)63307-2.

Yap JY, O'Connor C, Mager DR, Taylor G, Roberts EA. Diagnostic challenges of nonalcoholic fatty liver disease (NAFLD) in children of normal weight. Clin Res Hepatol Gastroenterol. 2011;35(6-7):500-505. doi:10.1016/j.clinre.2011.04.001.

Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol. 2012;25(3):218-231.

Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362-373. doi:10.1016/S2468-1253(19)30383-8.

Monteiro PA, Antunes Bde M, Silveira LS, Christofaro DG, Fernandes RA, Freitas Junior IF. Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents. BMC Pediatr. 2014;14:25. doi:10.1186/1471-2431-14-25.

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi:10.1016/j.jhep.2015.11.004.

Ohkawara K, Tanaka S, Miyachi M, Ishikawa-Takata K, Tabata I. A dose-response relation between aerobic exercise and visceral fat reduction: systematic review of clinical trials. Int J Obes (Lond). 2007;31(12):1786-1797. doi:10.1038/sj.ijo.0803683.

DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104-1115. doi:10.1056/NEJMoa1010949.

Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117(5):662-668. doi:10.1017/S0007114517000204.

Published

2021-09-06

How to Cite

Stepanov, Y., & Zavhorodnia, O. (2021). Nonalcoholic fatty liver disease in normal weight subjects: current concepts and approaches (literature review). GASTROENTEROLOGY, 54(3), 179–187. https://doi.org/10.22141/2308-2097.54.3.2020.211738

Issue

Section

Reviews and Lections

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>